Myrexis, Inc. is considering multiple strategic alternatives and its Board of Directors has retained Stifel Nicolaus Weisel to assist it in reviewing and evaluating a full range of strategic alternatives available to enhance shareholder value. Myrexis has also suspended development activities on all its pre-clinical and clinical programs. Myrexis is committed to conducting its review of potential alternatives as promptly as practicable.